Name | Pomalidomide |
Synonyms | CC-4047 ActiMid Pomalidomide Pomalidomide(CC-4047) Pomalidomide(CC-4047,Actimid) 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-AMino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione 1H-Isoindole-1,3(2H)-dione,4-aMino-2-(2,6-dioxo-3-piperidinyl)- |
CAS | 19171-19-8 |
EINECS | 805-902-5 |
InChI | InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) |
InChIKey | UVSMNLNDYGZFPF-UHFFFAOYSA-N |
Molecular Formula | C13H11N3O4 |
Molar Mass | 273.24 |
Density | 1.570±0.06 g/cm3(Predicted) |
Melting Point | 318.5 - 320.5° |
Boling Point | 582.9±45.0 °C(Predicted) |
Flash Point | 306.3°C |
Solubility | DMSO:54 mg/mL (197.62 mM);Water :Insoluble;Ethanol :Insoluble mother liquor preservation: sub-packaging and freezing to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 |
Vapor Presure | 1.41E-13mmHg at 25°C |
Appearance | Light yellow to yellow solid |
Color | yellow |
Merck | 14,135 |
pKa | 10.75±0.40(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
Refractive Index | 1.691 |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | Pomalidomide inhibits lipopolysaccharide (LPS)-stimulated release by TNF-alpha, with IC50 values of 13 nM and 25 nM for human PBMC and total human blood, respectively. Pomalidomide inhibited IL-2 of stimulated T regulatory cells with an IC50 of ~ 1 μm. Treatment of human peripheral blood T cells with 6.4 nM-10 μm Pomalidomide increased production by IL-2 and was more effective on the CD4 + subset than on the CD8 + subset. Pomalidoride significantly promoted IFN-γ by CC-5013, IL-2, and IL-5 over IL-10, and slightly promoted IFN-γ over CC-5013. Pomalidomide acts on Jurkat cells to enhance the AP-1 transcriptional activity induced by SEE and Raji cells, up to 4-fold at 1 μm, in a dose-dependent manner. Treatment of Raji cells with different concentrations of pomalido IDE (2.5-40 μg/mL) for 48 hours resulted in a significant decrease in cell proliferation and DNA synthesis by-40% compared to the control group. |
In vivo study | Pomalidomide acts on SCID mice to enhance the anticancer effect of Rituximab on B- cell lymphoma. The combination of pomalidoxide and Rituximab resulted in an average life span of 74 days in mice and 58 days in mice treated with CC5013/Rituximab. NK cell depletion completely abolished the synergistic effect of pomalidoride and Rituximab, indicating that the increase in NK cells is a mechanism by which pomalidoride enhances the anticancer effect of Rituximab. |
WGK Germany | 3 |
RTECS | NR3397905 |
HS Code | 29251900 |